Health Catalyst Management

Management criteria checks 2/4

Health Catalyst's CEO is Dan Burton, appointed in Oct 2012, has a tenure of 12.58 years. total yearly compensation is $5.49M, comprised of 9.6% salary and 90.4% bonuses, including company stock and options. directly owns 1.44% of the company’s shares, worth €3.64M. The average tenure of the management team and the board of directors is 2.3 years and 5.3 years respectively.

Key information

Dan Burton

Chief executive officer

US$5.5m

Total compensation

CEO salary percentage9.56%
CEO tenure12.6yrs
CEO ownership1.4%
Management average tenure2.3yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dan Burton's remuneration changed compared to Health Catalyst's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$73m

Dec 31 2024US$5mUS$525k

-US$70m

Sep 30 2024n/an/a

-US$79m

Jun 30 2024n/an/a

-US$86m

Mar 31 2024n/an/a

-US$106m

Dec 31 2023n/an/a

-US$118m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$147m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$4mUS$150k

-US$137m

Sep 30 2022n/an/a

-US$151m

Jun 30 2022n/an/a

-US$145m

Mar 31 2022n/an/a

-US$147m

Dec 31 2021US$6mUS$300k

-US$153m

Sep 30 2021n/an/a

-US$147m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$126m

Dec 31 2020US$5mUS$315k

-US$115m

Sep 30 2020n/an/a

-US$86m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$181m

Dec 31 2019US$4mUS$350k

-US$241m

Sep 30 2019n/an/a

-US$304m

Jun 30 2019n/an/a

-US$282m

Mar 31 2019n/an/a

-US$190m

Dec 31 2018US$5mUS$315k

-US$114m

Compensation vs Market: Dan's total compensation ($USD5.49M) is above average for companies of similar size in the German market ($USD810.57K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.


CEO

Dan Burton (48 yo)

12.6yrs

Tenure

US$5,494,141

Compensation

Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has strategy and leaders...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Burton
CEO & Director12.6yrsUS$5.49m1.44%
€ 3.6m
Jason Alger
Chief Financial Officer1.2yrsUS$1.29m0.050%
€ 127.1k
Benjamin Landry
General Counsel & Secretary of the Board2yrsUS$1.57m0%
€ 0
Linda Llewelyn
Chief People Officer7.3yrsUS$1.41m0.043%
€ 109.4k
Kevin Freeman
Chief Commercial Officerno dataUS$2.16m0.19%
€ 470.9k
Daniel LeSueur
Chief Operating Officer1.2yrsno data0.30%
€ 749.5k
Dave Ross
Chief Technology Officer2.7yrsno datano data
Amanda Flanders
Senior Vice President of Marketing & Communicationsless than a yearno datano data
Kyle Salyers
Chief Strategy Officer & Senior VP of Corporate Developmentno datano datano data
Jeffrey Selander
Senior Vice President of International6yrsno datano data
Holly Rimmasch
Senior VP & Chief Clinical Officerno datano datano data
Leslie Falk
Chief Client Success Officerno datano datano data

2.3yrs

Average Tenure

46.5yo

Average Age

Experienced Management: 2YP's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel Burton
CEO & Director13.7yrsUS$5.49m1.44%
€ 3.6m
John Kane
Independent Chairman9.3yrsUS$316.16k0.16%
€ 414.0k
Julie Larson-Green
Independent Director5.3yrsUS$233.49k0.072%
€ 183.7k
S. Smith
Independent Director5.3yrsUS$237.25k0.064%
€ 162.6k
Duncan Gallagher
Independent Director8yrsUS$244.77k0.075%
€ 190.0k
Jill Green
Directorless than a yearno data0.040%
€ 100.9k
Matthew Kolb
Independent Director1.8yrsno datano data

5.3yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 2YP's board of directors are considered experienced (5.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 00:25
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Health Catalyst, Inc. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhilin LongBerenberg
David LarsenBTIG
Richard CloseCanaccord Genuity